Reply to S. Chakrabarti et al, R. Cohen et al, and D.C. Guven

Affiliations

¹ Richard Gray, MSc, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Matt Seymour, MD, St James's University Hospital, Leeds, United Kingdom; Laura Magill, PhD and Kelly Handley, PhD, University of Birmingham Clinical Trials Unit, Birmingham, United Kingdom; Philip Quirke, MD and Nick West, MD, Division of Pathology and Data Analytics, School of Medicine, University of Leeds, Leeds, United Kingdom; and Dion Morton, MD, University Hospital Birmingham, Birmingham, United Kingdom.

Comment

Richard Gray et al. J Clin Oncol. 2023.

. 2023 Oct 20;41(30):4823-4824.

doi: 10.1200/JCO.23.00694. Epub 2023 Jul 18.

¹ Richard Gray, MSc, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Matt Seymour, MD, St James's University Hospital, Leeds, United Kingdom; Laura Magill, PhD and Kelly Handley, PhD, University of Birmingham Clinical Trials Unit, Birmingham, United Kingdom; Philip Quirke, MD and Nick West, MD, Division of Pathology and Data Analytics, School of Medicine, University of Leeds, Leeds, United Kingdom; and Dion Morton, MD, University Hospital Birmingham, Birmingham, United Kingdom.

No abstract available

Comment on

FOxTROT Study Results: Some Burning Questions Need Answers.
Chakrabarti S, Mahipal A. Chakrabarti S, et al. J Clin Oncol. 2023 Oct 20;41(30):4822-4823. doi: 10.1200/JCO.23.00359. Epub 2023 Jul 18. J Clin Oncol. 2023. PMID: 37463396 No abstract available.